mobile menu icon

Claire Phipps-Jones quoted on the Managing IP Magazine



The UK Supreme Court’s ruling in Actavis v Icos is likely to satisfy pharmaceutical and generics companies according to lawyers involved in the case.

“For Claire Phipps-Jones, patentees will welcome the clarification that dosage regimes that are the product of well-established or routine enquiries may be patentable. However, she adds ‘If a patented dosage regimen was unexpected at the priority date, but would have been arrived at without hindsight following the consideration of the results of routinely performed dose-ranging studies (including any follow-up testing), it is unlikely to withstand judicial scrutiny.”

Read the full article on the Managing IP Magazine, March 2019.

Share to: